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ABSTRACT 
Dopamine, serotonin and noradrenaline are the major monoamines in the 
human central nervous system (CNS) and following their basic pathways they 
are degraded to their major metabolites homovanillic acid (HVA), 5-
hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol 
(MHPG), respectively. The cerebrospinal fluid (CSF) concentrations of the 
three monoamine metabolites (MM) are considered to reflect the monoamine 
turnover rates in the CNS, are under genetic influence and have been 
associated with schizophrenia.  
In the first part of the thesis (Studies I, II and III), 132 healthy individuals (78 
men and 54 women) were included, whereas in the second part of the thesis 
(Studies IV and V) 74 psychotic patients (45 men and 29 women) participated. 
CSF samples were drawn by lumbar puncture and genomic DNA was extracted 
from whole blood samples for genotyping.  
In the first part of the thesis, we have searched for association between single 
nucleotide polymorphisms (SNPs) in the tryptophan hydroxylase 1 (TPH1), 
dystrobrevin binding protein 1 (DTNBP1) and D-amino acid oxidase activator 
(DAOA) genes and the CSF MM concentrations in healthy individuals in order 
to shed further light to the understanding of the effect of the genes on CSF MM 
in humans. One TPH1 SNP and one DTNBP1 SNP were found to be 
significantly associated with both CSF 5-HIAA and HVA, giving evidence for 
association between the genes and dopamine and serotonin turnover rates in 
CNS. Two DAOA SNPs were significantly associated with CSF HVA 
concentrations, proposing that the DAOA gene is implicated in dopaminergic 
mechanisms. 
In the second part of the thesis, we searched for association between genes 
implicated in dopamine, serotonin and noradrenalin metabolism (Study IV) and 
glutamate-related genes (Study V) and CSF MM concentrations in psychotic 
patients. Several nominal associations and one significant association between 
MAOB and MHPG in men (Study IV) were found, suggesting that CSF MM 
concentrations can be considered as psychosis intermediate phenotypes in 
previously reported associations between gene variants and the disorder. 
Keywords: Cerebrospinal fluid (CSF), homovanillic acid (HVA), 5-
hydroxyindoleacetic acid (5-HIAA), 3-methoxy-4-hydroxyphenylglycol 
(MHPG), psychiatric genetics, single nucleotide polymorphisms (SNPs), 
schizophrenia, psychosis, intermediate phenotypes, healthy individuals  
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1 INTRODUCTION 
 
The present thesis focuses on the association between genetics and the 
monoamines, dopamine, serotonin and noradrenaline in the central nervous 
system (CNS), aiming to shed further light to the hypothesis that gene variants 
affect the monoamine systems in different populations. Dopamine, serotonin 
and noradrenaline are the major monoamines in the human CNS and following 
their basic biochemical pathways they are degraded to their major metabolites 
homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-
methoxy-4-hydroxyphenylglycol (MHPG), respectively (Figure 1). Throughout 
the thesis, the cerebrospinal fluid (CSF) concentrations of HVA, 5-HIAA and 
MHPG have been used as the outcomes. The population of interest in the first 
part of the thesis is healthy subjects, whereas the second part of the thesis 
focuses on psychotic patients.  
 
1.1 DOPAMINE, SEROTONIN AND NORADRENALINE 
The neurotransmitters dopamine, serotonin and noradrenaline are the major 
monoamines in CNS. Dopamine and noradrenalin are also referred to as 
catecholamines. The prefrontal cortex, implicated in higher executive processes, 
is interconnected with several cortical and subcortical structures, including the 
brainstem monoamine nuclei (Hensler et al., 2013). 
The three monoamines, often viewed in isolation, modulate specific brain 
functions. Dopamine is involved in cognition as well as motivation and reward 
(Tzschentke, 2001; Vallone et al., 2000). Serotonin (5-hydroxytryptamine) is 
implicated in the regulation of mood, sleep and appetite as well as in perception 
and several cognitive processes, whereas noradrenaline (norephinephrine) 
modulates arousal, concentration and attention as well as learning and memory 
(Hensler et al., 2013; Ressler and Nemeroff, 1999; Saxena, 1995). 
Several lines of evidence from more recent neuroanatomical and neurochemical 
studies have given evidence for significant functional interactions and 
anatomical interconnections between the three monoamine systems in CNS. 
These interacting systems regulate brain functions, such as cognition, emotion, 
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motor function and coordination. Their dysregulation has been associated with 
numerous mental and other disorders, including schizophrenia (Hensler et al., 
2013). 
 
1.2 CEREBROSPINAL FLUID MONOAMINE METABOLITES 
 
1.2.1 CSF monoamine metabolites and monoamine turnover rates 
in central nervous system 
HVA, 5-HIAA and MHPG are the major degradation products of dopamine, 
serotonin and noradrenaline, respectively (Figure 1). The concentrations of the 
three monoamine metabolites (MM) can be measured in the CSF and they are 
considered to represent, mainly HVA and 5-HIAA, indirect indexes of the 
monoamine turnover rates in the CNS. Concentrations of HVA and 5-HIAA in 
ventricular, cisternal, and lumbar CSF show a craniocaudal gradient (Moir et al., 
1970; Nordin et al., 1982; Wiesel, 1975). Postmortem human studies have shown 
that CSF HVA and 5-HIAA reflect brain HVA and 5-HIAA concentrations 
(Knott et al., 1989; Stanley et al., 1985; Wester et al., 1990). CSF HVA 
concentrations correlate with nigrostriatal dopamine function in Parkinson’s 
disease (Ishibashi et al., 2010). The results suggest that a significant proportion 
of the lumbar HVA and 5-HIAA derives from the brain. In addition, there is a 
well established positive correlation between CSF 5-HIAA and HVA, mainly in 
healthy individuals (Hsiao et al., 1993). 
On the other hand, CSF MHPG has been reported to mainly derive from 
noradrenergic nerves in the spinal cord and the blood compartment (Kopin et al., 
1983; Post et al., 1973). However, a more recent study have shown a 
significantly positive correlation between CSF MHPG and MHPG 
concentrations in hypothalamus, temporal cortex, and pons in human autopsy 
cases (Wester et al., 1990), suggesting that CSF MHPG can also be used for the 
purpose of the thesis.  
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1.2.2 CSF monoamine metabolites and genetics 
In humans, CSF MHPG is under major genetic influence, whereas CSF 5-
HIAA and HVA are under both genetic and environmental influence 
(Oxenstierna et al., 1986). Studies in other primates also indicate that CSF 
concentrations of the MM are partially under genetic influence (Higley et al., 
1993; Rogers et al., 2004). 
 
1.2.3 CSF monoamine metabolites and schizophrenia 
Schizophrenia has been associated with monoamine metabolite concentrations, 
mainly HVA. HVA concentrations have been reported to be significantly lower 
in drug-free patients with schizophrenia when compared to controls 
(Bjerkenstedt et al., 1985; Lindstrom, 1985; Wieselgren and Lindstrom, 1998). 
Both quetiapine and olanzapine administration have been associated with a 
significant increase in CSF HVA (Nikisch et al., 2010; Scheepers et al., 2001). 
Elevated MHPG concentrations have been shown in patients with psychosis 
(Hsiao et al., 1993). Moreover, untreated psychotic patients showed 
substantially lower correlation between HVA and 5-HIAA concentrations 
relative to controls. This correlation, which is almost linear in healthy controls, 
was normalized after treatment (Hsiao et al., 1993). 
 
1.3 PSYCHOSIS 
1.3.1 DSM and ICD 
There are two main systems of classification for psychiatric diagnoses, the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) developed by the 
American Psychiatric Association and the International Classification of 
Diseases (ICD) developed by the World Health Organization.  
In Studies IV and V, the patients were diagnosed according to the Diagnostic 
and Statistical Manual of Mental Disorders, Third Edition - Revised (DSM-III-
R)  after a diagnostic interview (Spitzer et al., 1988) and according to DSM-III-
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R (American Psychiatric Association, 1987) and the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric 
Association, 1995) after retrieving data from medical records. The final 
diagnoses were the ICD (8th, 9th or 10th revisions) hospital discharge 
diagnoses from the Swedish psychiatric inpatient register (SPIR).  
 
1.3.2 Schizophrenia and related disorders 
A classification of the psychotic disorders according to the latest DSM version, 
i.e. the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5) (American Psychiatric Association, 2013) and the latest ICD version 
(ICD-10) (World Health Organisation, 1992) is illustrated. The criteria for 
schizophrenia, according to DSM-5 as well as the main differences relative to 
the previous versions are also given. 
In DSM-5, the following disorders are listed as schizophrenia spectrum and 
other psychotic disorders: schizotypal personality disorder, delusional disorder, 
brief psychotic disorder, schizophreniform disorder, schizophrenia, 
schizoaffective disorder, substance/medication-induced psychotic disorder, 
psychotic disorder due to another medical condition, catatonia, other specified 
schizophrenia spectrum and other psychotic disorder and unspecified 
schizophrenia spectrum and other psychotic disorder. In ICD-10 the following 
disorders are listed as schizophrenia and schizotypal and delusional disorders: 
Schizophrenia (including other schizophrenia, corresponding to DSM-IV 
schizophreniform disorder), schizotypal disorder, persistent delusional 
disorders, acute and transient psychotic disorders, induced delusional disorder, 
schizoaffective disorders, other nonorganic psychotic disorders and unspecified 
nonorganic psychosis.  
Briefly, delusions, hallucinations, disorganized speech, grossly disorganized or 
catatonic behavior and negative symptoms (at least two of these symptoms and 
at least one of the first three have to be present) during one month or less if 
successfully treated, characterize schizophrenia according to DSM-5 (Criterion 
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A). Moreover, the level of functioning in major areas is markedly below the 
level before the onset of the disorder and continuous signs persist for at least six 
months, including prodromal and residual periods. Schizoaffective disorder, 
depressive and bipolar disorder with psychotic features, substance/medication-
induced psychotic disorder and psychotic disorder due to another medical 
condition have been ruled out. In the case of autism or a communication 
disorder, an additional diagnosis of schizophrenia is made only if prominent 
delusions or hallucinations are present.  
In DSM-5, two Criterion A symptoms are required for a schizophrenia diagnosis, 
whereas in DSM-IV, only one Criterion A symptom is required in the case of 
bizarre delusions or auditory hallucinations consisting of a voice commenting 
on the patient's thoughts or behavior, or voices conversing with each other. In 
DSM-IV Criterion A, there is no requirement for at least one of the following 
symptoms: delusions, hallucinations, and disorganized speech. The DSM-IV, 
schizophrenia subtypes are eliminated in DSM-5. In DSM-III-R, the required 
duration for active phase symptoms is one week or less if successfully treated, 
whereas in ICD-10, DSM-IV and DSM-5 the required duration is one month.  
 
1.4 GENETICS 
Genetic research uses numerous study designs, investigating families or 
unrelated individuals. Family studies with family history or family study 
approach have been used, searching for familial aggregation. Moreover, 
numerous twin and adoption studies have been conducted, where the researcher 
is trying to explain the familial aggregation, differentiating environmental and 
genetic factors. Linkage studies (model-based and model-free linkage analysis) 
have been extensively used in order to localize the chromosomal region, in 
which the relevant genetic variant is located.    
Another study design is the association analysis with unrelated individuals, 
searching for associations between specific gene variants and a phenotype. In 
the investigation of complex diseases, association studies have been mostly 
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used as they have a greater power and genetic resolution relative to linkage 
studies (Risch and Merikangas, 1996). Due to the possibility of population 
stratification, an alternative analysis of association within families has also 
been used (Laird and Lange, 2006). Genetic association studies search for 
association between specific gene variants, candidate genes, chromosomal 
regions or the whole genome and a phenotype.  
Two major classes of human genome variants have been identified, i.e. structural 
variants, mainly attributable to insertions, deletions, block substitutions, 
inversions and copy number variants (CNVs) and single nucleotide variants 
(Frazer et al., 2009; Sachidanandam et al., 2001). Single nucleotide 
polymorphisms (SNPs) are variants in only one base, which is substituted with 
another and are the most abundant form of variation in human deoxyribonucleic 
acid (DNA), occurring on average every 1-2 kb (Sachidanandam et al., 2001).  
 
Genome Wide Association Studies (GWAS) have revolutionized the field of 
genetic research, as SNPs covering the whole genome are investigated for 
association with the phenotype of interest, without a priori biological 
hypotheses. If an association is found between a SNP and a phenotype, this can 
be attributable to a direct association, reflecting a causal association between the 
SNP and the phenotype or to an indirect association due to the fact that the 
associated SNP is in strong linkage disequilibrium (LD) with another genetic 
locus, which affects the phenotype. LD describes the deviation from 
independence between the alleles at two or more genetic loci. 
As both common and rare variants are likely to contribute to the genetic 
architecture of complex disorders, such as the psychiatric disorders, recent 
advances in next-generation sequencing have made possible the discovery of 
rare variants, using whole-exome sequencing, i.e. sequencing of the 1% of the 
human genome encoding proteins, or whole-genome sequencing (Ezewudo and 
Zwick, 2013). 
The epigenetic information, superimposed upon the DNA sequence, is also a 
focus of current research. It is mainly stored as DNA methylation (mainly 
methylation of cytosines in cytosine/guanine dinucleotides) and histone 
modifications and it is determined by genetic and environmental factors 
(Bernstein et al., 2007). There is an increasing interest in exploring how 
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epigenetic factors are implicated in disease aetiology and epigenetic studies, 
including epigenome-wide association studies, create new opportunities for the 
understanding of complex disesases (Rakyan et al., 2011). 
In the present thesis, SNPs in different genes have been used as genetic 
markers and have been investigated for association with our outcomes of 
interest, i.e. the CSF MM concentrations in different populations. The SNPs 
selected in our studies were either candidate SNPs, previously reported to be 
associated with schizophrenia, other mental disorders, monoamine metabolite 
concentrations or having other known functionality, or tag-SNPs, selected to 
cover the investigated genes with an r
2
 threshold of 0.8. Tag-SNPs capture 
surrounding SNP information because of the presence of LD and serve 
therefore as proxies for correlated SNPs that are not genotyped. 
 
1.5 HEALTHY SUBJECTS AND OUR HYPOTHESES IN THE FIRST 
PART OF THE THESIS (STUDIES I-III) 
In the first part of the thesis, we searched for association between markers in 
the tryptophan hydroxylase 1 (TPH1), dystrobrevin binding protein 1 
(DTNBP1) and D-amino acid oxidase activator (DAOA) genes and CSF HVA, 
MHPG and 5-HIAA in healthy individuals. Our main interest was to test the 
hypothesis that TPH1, DTNBP1 and DAOA gene variations affect the 
dopamine, serotonin and noradrenaline turnover rates in healthy humans. The 
selection of the three genes was not at random, but was based on the fact that 
these genes are expected to influence the monoamine systems due to 
biochemical or functional associations. Associations between gene variants and 
different biological markers are generally of great interest as they shed further 
light to the understanding of gene functionality in healthy humans, in other 
words the effect of genetics on physiology. As the selection of the genes and 
SNPs was also based on their associations with schizophrenia, positive results 
may indirectly suggest that disturbed monoamine metabolism is a mechanism 
behind the previously reported associations between gene variants and 
psychosis in humans. This question is directly addressed in the second part of 
the thesis, where psychotic patients participate. To our knowledge, the studies 
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of the present thesis are the first studies searching for association between 
DTNBP1 and DAOA gene variants and CSF MM in healthy subjects, whereas 
in the case of TPH1, there are previous studies searching for association 
between some of our included SNPs and CSF MM with partially discordant 
results. These TPH1 studies and their results are illustrated in the discussion of 
Study I.  
 
 
1.6 PSYCHOSIS AND OUR HYPOTHESES IN THE SECOND PART 
OF THE THESIS (STUDIES IV-V) 
Schizophrenia is a mental disorder with substantial morbidity and mortality, 
affecting around 1% of the world’s population (Millier et al., 2014; Tandon et 
al., 2008). The disorder has a high heritability, considered to be up to 80% 
(Sullivan et al., 2012). Two of the most influential theories concerning the 
pathophysiology of the disorder implicate dopamine and glutamate dysfunctions, 
followed by other theories implicating the serotonergic, cholinergic, and 
GABAergic systems (Howes et al., 2015; Laruelle, 2014). 
Several lines of evidence, including pharmacological, post-mortem and in vivo 
imaging  studies, support the classical dopamine hypothesis of schizophrenia 
(Howes et al., 2015). The most robust evidence comes probably from 
pharmacological studies showing the efficacy of antipsychotics to block 
dopamine D2 receptors in a dose-dependent manner as well as the psychotogenic 
effect of dopamine enhancing substances (Laruelle, 2014). It has been suggested 
that positive psychotic symptoms are associated with excessive stimulation of 
dopamine D2 receptors in subcortical brain regions, mainly striatum, whereas 
negative and cognitive psychotic symptoms may be due to a lack of stimulation 
of dopamine D1 receptors in prefrontal cortex (Laruelle, 2014). 
Glutamate, deriving from glucose and glutamine, is the major excitatory 
neurotransmitter in CNS and is implicated in several neural processes, such as 
neuronal development and plasticity (Goff and Coyle, 2001). Several lines of 
evidence, including CSF studies (Kim et al., 1980), studies on glutamate 
antagonists that can induce or exacerbate psychotic symptoms (Krystal et al., 
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1994; Lahti et al., 1995), as well as pathological studies (Mueller and Meador-
Woodruff, 2004; Nudmamud-Thanoi and Reynolds, 2004) have given evidence 
for an implication of the glutamate system in the pathophysiology of 
schizophrenia. Multiple interactions and associations have been identified 
between the glutamatergic system and dopamine, serotonin and noradrenaline 
(Feldman and Weidenfeld, 2004; Missale et al., 2006). 
Several monoamine-related and glutamate-related genes have been reported to 
be associated with schizophrenia in independent studies, however the results 
have been ambiguous and difficult to replicate in subsequent studies. A recent 
GWAS of more than 100 000 individuals showed genome wide significant 
associations between the dopamine D2 receptor gene and a number of genes 
related to glutamatergic neurotransmission and schizophrenia (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014). 
In the second part of the thesis (Studies IV and V), we have searched for 
association between genes related to monoamine metabolism (Study IV) and 
glutamate-related genes (Study V) and CSF MM concentrations in psychosis. 
To our knowledge, there are no previous studies searching for association 
between gene variants and CSF MM in psychotic patients.  
The approach used in this part of the thesis, i.e. the investigation of possible 
associations between gene variants and psychosis intermediate phenotypes, is a 
powerful approach that can lead to a better understanding of the associations 
between genotypes and phenotypes, as well as to more robust results (Bilder et 
al., 2009; Freimer and Sabatti, 2003). Intermediate phenotypes are mechanism-
related manifestations of a complex phenotype, in this case the highly complex 
psychotic disorder (Goldman and Ducci, 2007). An endophenotype meets 
specific criteria, i.e. association with the disorder, heritability and state-
independence. Moreover, within families, the endophenotype and the disorder 
co-segregate. The endophenotype is found in nonaffected family members at a 
higher rate relative to general population (Gottesman and Gould, 2003). The 
term intermediate phenotype is used by many authors for traits that have not 
been formally shown to meet the criteria for endophenotypes, whereas other 
authors use the two terms interchangeably (Goldman and Ducci, 2007; 
Gottesman and Gould, 2003). Biochemical, endocrinological, neuroanatomical 
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neurophysiological and neuropsychological measures have been used as 
putative endophenotypes/intermediate phenotypes (Gottesman and Gould, 
2003). 
As MM concentrations have been reported to be heritable in human and other 
primates (Higley et al., 1993; Oxenstierna et al., 1986; Rogers et al., 2004) and 
to some extent psychosis-related (Bjerkenstedt et al., 1985; Lindström, 1985; 
Wieselgren and Lindstrom, 1998), but do not formally fulfill all the 
endophenotype-related criteria required, the terms intermediate steps and 
intermediate phenotypes have been used in Studies IV and V, to characterize 
the monoamine metabolite concentrations relative to psychosis. 
 
1.7 INVESTIGATED GENES 
 
1.7.1 Genes encoding enzymes implicated in monoamine 
metabolism (Studies I and IV) 
The following genes encode the major enzymes involved in dopamine, 
serotonin and noradrenaline pathways (Figure 1). Due to this direct 
biochemical connection, functional variations in the selected genes are 
expected to affect the major degradation products of the monoamine pathways, 
i.e. HVA, 5-HIAA and MHPG.  
The TPH1 and tryptophan hydroxylase 2 (TPH2) genes are located on 
chromosome 11p15.3–p14 and 12q21.1, respectively. The two genes encode 
the two active isoforms, TPH1 and TPH2, of the enzyme TPH. TPH catalyzes 
the first and rate-limiting step in the serotonin metabolism, converting 
tryptophan to 5-hydroxytryptophan (Cooper and Melcer, 1961). Both isoforms 
are expressed in CNS, with the TPH2 messenger RNA (mRNA) preferentially 
expressed in the brain, whereas TPH1 preferentially expressed in pineal gland 
and the periphery as well as during later developmental brain stages (Nakamura 
et al., 2006; Walther et al., 2003). 
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The tyrosine hydroxylase gene (TH) is located on chromosome 11p15.5. TH 
catalyzes the rate-limiting step in the biosynthesis of catecholamines, i.e. the 
conversion of L-tyrosine to 3,4-dihydroxy-L-phenylalanine (L-DOPA). 
 
Tryptophan
5-Hydroxytryptophan
5-Hydroxytryptamin (serotonin)
5-Hydroxyindoleacetic acid (5-HIAA)
Tryptophan hydroxylase
Aromatic amino acid 
decarboxylase
Monoamine oxidase (MAO) +
Aldehyde dehydrogenas
Tyrosine
Dihydroxyphenylalanine (DOPA)
Dopamine
Tyrosine hydroxylase
Aromatic amino acid 
decarboxylase
Dopamine beta-hydroxylase
3,4-Dihydroxyphenylacetic acid   3-Methoxytyramine
Homovanillic acid (HVA)
MAO
Norepinephrine
3,4-
Dihydroxyphenylglycolaldehyde
3,4-Dihydroxyphenylglycol
3-Methoxy-4-
hydroxyphenylglycol (MHPG)
Catechol-O-methyltransferase (COMT)
COMT
MAO
MAO
Aldehyde reductase
COMT
Figure 1. Dopamine, serotonin and noradrenaline pathways.  
 
The DOPA decarboxylase gene (DDC) is located on chromosome 7p12.1. 
DDC, also known as aromatic L-amino acid decarboxylase, is implicated in 
both serotonin and catecholamine metabolism, catalyzing the decarboxylation 
of L-DOPA to dopamine and 5-hydroxytryptophan to serotonin.  The dopamine 
beta-hydroxylase gene (DBH) is located on chromosome 9q34. DBH, localised 
in the vesicles of catecholaminergic cells,  is involved in the metabolism of the 
catecholamines, catalyzing the hydroxylation of dopamine to noradrenaline 
(Kemper et al., 1987).  
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The catechol-O-methyltransferase gene (COMT) is located on chromosome 
22q11.2. COMT catalyzes the inactivation of both dopamine and noradrenaline 
and thus regulates the degradation of the catecholamines, being the most 
important regulator of the prefrontal dopamine function (Sagud et al., 2010). 
The monoamine oxidase A (MAOA) and monoamine oxidase B (MAOB) genes 
are closely linked on chromosome Xp11.23. MAOA and MAOB encodes the 
two enzyme forms, i.e. MAOA and MAOB, respectively. MAOA and MAOB 
are located in the outer mitochondrial membrane, with MAOA preferentially 
oxidizing serotonin and noradrenaline and MAOB oxidizing dopamine (Shih et 
al., 1999).  
TPH1, TH, DBH, COMT, MAOA and MAOB gene variants have been 
associated with schizophrenia in individual studies with positive meta-analyses 
for TPH1 and COMT (www.szgene.org). TPH2 has been associated with the 
severity of psychotic symptoms in schizophrenia (Zhang et al., 2011), whereas 
DDC has been associated with the age of disease onset in psychotic men 
(Børglum et al., 2001).  
 
1.7.2 Glutamate-related genes (Study V), DTNBP1 (Study II) and 
DAOA (Study III) 
The glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 1 (GRIN1) 
and glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 2B (GRIN2B)  
genes are located on chromosomes 9q34.3 and 12p12, respectively and encode 
different subunits of the N-methyl-D-aspartate receptors (NMDARs), which are 
glutamate receptors implicated in memory, neurodevelopment and learning 
(Hirasawa et al., 2003; Riedel et al., 2003).  
The DAOA gene is located on chromosome 13q34, whereas the D-amino acid 
oxidase gene (DAO) is located on chromosome 12q24.  The product of DAOA, 
the DAOA protein, has been found in various brain regions (Chumakov et al., 
2002) and modulates the function of DAO, an enzyme catalyzing the oxidative 
deamination of D-amino acids, including D-3,4-dihydroxyphenylalanine (D-
DOPA) and D-serine (Kawazoe et al., 2007; Wu et al., 2006). D-DOPA is 
converted to L-DOPA (Kawazoe et al., 2007; Wu et al., 2006), a precursor of 
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dopamine, whereas D-serine is implicated in glutamatergic neurotransmission 
(Mothet et al., 2000). The biochemical and functional connections of DAOA and 
DAO with the MM are illustrated in Figure 2. 
 
Figure 2. Biochemical and functional connections between D-amino acid oxidase 
activator and cerebrospinal fluid monoamine metabolites. 
 
 
The disrupted in schizophrenia 1 gene (DISC1) is located on chromosome 1q42 
and encodes DISC1, a protein implicated in neurodevelopment, neural plasticity 
and migration (Thomson et al., 2013). It modulates serine racemase, an enzyme 
affecting glutamate neurotransmission (Snyder and Gao, 2013). 
The brain-derived neurotrophic factor gene (BDNF) is located on chromosome 
11p13. Its product, BDNF, is a neurotrophic factor with critical function for 
neural development, survival and regeneration (Balaratnasingam and Janca, 
2012; Nurjono et al., 2012). BDNF is implicated in the glutamatergic and 
monoaminergic neurotransmission (Nurjono et al., 2012). 
The DTNBP1 gene is located on chromosome 6p22.3. DTNBP1 encodes 
dysbindin, a protein implicated in dopaminergic and glutamatergic 
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neurotransmission (Talbot et al., 2004; Weickert et al., 2004). Dysbindin is a 
component of protein complexes in CNS, involved in synaptic structure and 
signaling, as well as in neurodevelopment (Benson et al., 2001; Ghiani et al., 
2010). 
The indoleamine 2,3-dioxygenase 1 (IDO1), tryptophan 2,3-dioxygenase 
(TDO2) and kynurenine 3-monooxygenase (KMO) genes are located on 
chromosomes 8p12-p11, 4q31-q32 and 1q42-q44, respectively and encode 
enzymes implicated in the kynurenine pathway of the tryptophan degradation 
(Myint and Kim, 2014; Schwarcz et al., 2012). A number of neuroactive 
metabolites deriving from this pathway, including the glutamate receptor 
antagonist kynurenic acid (Schwarcz et al., 2012), are involved in glutamatergic 
and monoaminergic neurotransmissions (Myint and Kim, 2014). 
GRIN1, GRIN2B, DAOA, DAO, DISC1, BDNF and DTNBP1 and KMO gene 
variants have been associated with schizophrenia in individual studies with 
DAOA showing evidence for association in two meta-analyses 
(www.szgene.org). DAOA has also been associated with  antipsychotic treatment 
response (Pae et al., 2010) and the progression of prodromal psychotic 
syndromes to psychosis (Mossner et al., 2010). 
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2 AIMS 
 
The overall objective of the thesis was to investigate the associations between 
relevant gene variants and the dopamine, serotonin and noradrenaline turnover 
rates in CNS, as reflected by the CSF concentrations of HVA, 5-HIAA and 
MHPG in psychotic patients and healthy individuals. 
The specific aims were: 
 
 To investigate the associations between TPH1, DTNBP1 and DAOA gene 
variants and  the CSF concentrations of HVA, 5-HIAA and MHPG in 
healthy controls (Studies I-III).  
 
 To evaluate the effect of genes encoding enzymes implicated in 
monoamine metabolism and glutamate-related genes on the CSF 
concentrations of HVA, 5-HIAA and MHPG in psychotic patients 
(Studies IV-V). 
 
 
 
 To evaluate  if  previously reported associations between gene variants 
and schizophrenia can be mediated by dopaminergic, serotonergic or 
noradrenergic mechanisms, as reflected by the CSF concentrations of 
HVA, 5-HIAA and MHPG in psychotic patients (Studies IV-V).  
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3 METHODS 
 
3.1 SUBJECTS 
 
3.1.1 Studies I-III 
In the first part of the thesis, 132 unrelated healthy Caucasians (78 men and 54 
women) were included. They were mostly students and hospital stuff or 
individuals drawn from a population register from Stockholm county council. 
The subjects had previously participated in studies regarding CSF and 
heritability factors (Oxenstierna et al., 1986; Sedvall et al., 1980; Wiesel et al., 
1982), or studies of CSF circulation (Oxenstierna et al., 1996). 
Sixty six out of the 132 healthy subjects had previously participated in studies, 
searching for association between gene variation and CSF monoamine 
metabolite concentrations (Jönsson et al., 1997; Jönsson et al., 1996; Jönsson et 
al., 1998). Moreover, about 90 of the subjects participated in further similar 
studies (Annerbrink et al., 2010; Damberg et al., 2004; Jönsson et al., 2004; 
Jönsson et al., 2000). More recently, all individuals (n=132) were included in a 
study, where the author of the thesis was also co-author, searching for 
association between BDNF SNPs and CSF HVA, 5-HIAA and MHPG 
concentrations (Jönsson et al., 2008). 
At the first diagnostic interview, when CSF samples were drawn, all 
participants were found to be healthy, i.e. the absence of psychiatric morbidity 
was ascertained. The subjects’ mean age ± standard deviation (SD) was 27 ± 9 
years at lumbar puncture. All participants were drug-free, with the exception of 
22 female participants, who used oral contraceptives. 
Eight to 20 years after the first interview, subjects were re-interviewed to re-
assess psychiatric morbidity (Jönsson et al., 2004; Jönsson et al., 2008) and 
whole blood was drawn for DNA extraction and genotyping. At this second 
interview, a structured interview was performed by psychiatrists to assess 
psychiatric (Spitzer et al., 1986) and somatic morbidity as well as the presence 
of psychiatric or nervous system disorders among relatives. If the subjects have 
been in contact with inpatient or outpatient psychiatric department, the records 
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were obtained and examined for diagnosis. Forty three of the subjects were 
found to fulfill criteria for a number of DSM-III-R psychiatric lifetime 
diagnoses: major depression and simple phobia (n=2), bipolar disorder, alcohol 
dependence and cannabis dependence (n=1), alcohol dependence and cannabis 
dependence (n=1), social phobia and simple phobia (n=1), depressive disorder 
not otherwise specified (NOS) and simple phobia (n=1), major depression 
(n=4), depressive disorder NOS (n=3), bipolar disorder (n=2), psychosis NOS 
(n=1), panic disorder (n=1), simple phobia (n=1), obsessive compulsive 
disorder (n=1), anxiety disorder NOS (n=1), somatoform disorder NOS (n=1), 
alcohol dependence (n=6), alcohol abuse (n=6), cannabis abuse (n=1), 
stuttering (n=1), bulimia nervosa (n=1), functional enuresis (n=2), adjustment 
disorder NOS (n=1), unspecified mental disorder (n=4).  
 
3.1.2 Studies IV-V 
In the second part of the thesis, patients with psychotic disorder were recruited 
among inpatients at four psychiatric university clinics in Stockholm County 
between 1973 and 1987 and were asked to participate in pharmacological or 
biological research projects (Bjerkenstedt et al., 1977; Härnryd et al., 1984; 
Oxenstierna et al., 1996; Wode-Helgodt et al., 1977). The participants were 
observed for at least 48 hours without any antipsychotic medication and CSF 
samples (12.5 ml) were drawn. 
Three to 34 years after the first investigation, patients were asked to participate 
in genetic research studies and whole blood was drawn for genotyping. Patients 
were asked to participate in a diagnostic structured interview (Spitzer et al., 
1988) and permit the researchers to retrieve their medical records. Available 
records were scrutinized by researchers to obtain a life-time diagnosis 
according to DSM-III-R and DSM-IV. In 2010, hospital discharge diagnoses 
were also obtained from the SPIR, a register covering all inpatient 
hospitalizations in Sweden since 1973. For each hospitalization the diagnosis 
was recorded according to the ICD, 8th, 9th or 10th revisions. The majority of 
the participants had experienced several hospitalizations, but only one 
diagnosis was given per participant, following a diagnostic hierarchy (Ekholm 
et al., 2005; Vares et al., 2006). The final diagnoses were based on the SPIR, as 
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it was not possible to retrieve all medical records and several of the patients 
were not willing to participate in a diagnostic interview. 
Seventy-four psychotic patients (45 men and 29 women) participated in the 
present study. The mean age of disease onset ± SD was 27.6 ± 7.8 years, 
whereas the patients’ mean age ± SD was 30.4 ± 7.2 years at lumbar puncture. 
Twenty-six of the patients were treated with antipsychotics at the time of 
lumbar puncture, whereas thirty-sex patients were free from antipsychotic 
medication since three weeks or longer. Sixty-four patients were diagnosed 
with schizophrenia spectrum disorder (schizophrenia n=60, schizoaffective 
disorder n=4) and ten with other psychosis (psychosis NOS n=7, delusional 
disorder n=1, bipolar disorder n=1, alcohol induced psychotic disorder n=1).  
 Analyses in healthy controls were conducted for SNPs that were nominally 
associated with monoamine metabolite concentrations in psychotic patients, in 
order to evaluate whether the effects of the associated SNPs were restricted to 
patients with psychosis. CSF samples were drawn by lumbar puncture from 
111 unrelated healthy Caucasians. Eight to 20 years after the first investigation, 
the subjects were interviewed to re-assess the absence of psychiatric morbidity 
(Jönsson et al., 2004) and whole blood was drawn for genotyping.  
 
3.2 CEREBROSPINAL FLUID SAMPLES 
CSF samples of 12.5 ml were drawn by lumbar puncture with the participants, 
both healthy subjects and psychotic patients, in a sitting or recumbent position. 
CSF was sampled between 8 and 9 a.m, after at least 8 hours of supervised 
bed-rest and absence of food intake or smoking. 5-HIAA, HVA, and MHPG 
concentrations were measured by mass fragmentography with deuterium-
labeled internal standards (Swahn et al., 1976). Back-length was defined as the 
distance between the external occipital protuberance and the point of needle 
insertion. 
  
 
  19 
3.3 GENOTYPING 
 
3.3.1 Studies I-III 
Genomic DNA was extracted from whole blood samples (Geijer et al., 1994). 
The investigated SNPs, selected due to previously reported association with 
schizophrenia, were genotyped at the SNP Technology Platform at Uppsala 
University and Uppsala University Hospital, Sweden 
(http://www.genotyping.se), using the Illumina BeadStation 500GX and the 
1536-plex Illumina Golden Gate assay (Illumina Inc., San Diego, CA, USA).  
Five TPH1 SNPs, i.e.rs4537731, rs211105, rs1800532, rs1799913 and 
rs7933505 were genotyped in Study I. Eleven DTNBP1 SNPs, i.e. rs12524251, 
rs760666, rs2619539, rs3213207, rs1011313, rs2619528, rs2619522, 
rs1018381, rs909706, rs2743852 and rs2619538, were genotyped in Study II 
and four DAOA SNPs, i.e. rs2391191, rs778294, rs3918342 and rs1421292 
were genotyped in Study III. 
 
3.3.2 Studies IV-V 
Genomic DNA was extracted from whole blood samples (Geijer et al., 1994). 
Candidate SNPs, previously associated with schizophrenia, other mental 
disorders, enzyme function or CSF monoamine metabolite concentrations, and 
tag-SNPs selected using HapMap to cover the investigated genes with an r
2
 
threshold of 0.8, were genotyped.  The genotyping was performed using the 
Illumina BeadStation 500GX and the 768-plex Illumina Golden Gate assay 
(Illumina Inc., San Diego, CA, USA (Fan et al., 2003). 
In study IV, 119 SNPs in eight genes, i.e. TPH1 (n=10), TPH2 (n=21), TH 
(n=10), DDC (n=24), DBH (n=25), COMT (n=16), MAOA (n=6) and MAOB 
(n=7) were genotyped. In study V, 238 SNPs in ten genes, i.e. GRIN1 (n=10), 
GRIN2B (n=5), DAOA (n=19), DAO (n=11), DISC1 (n=122), BDNF (n=10), 
DTNBP1 (n=26), KMO (n=25), IDO1 (n=3) and TDO2 (n=7) were genotyped.  
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3.4 STATISTICAL ANALYSIS 
 
3.4.1 Studies I-III 
In the first part of the thesis (Studies I-III), the associations between SNPs and 
CSF MM concentrations were tested with a general linear model (Proc GLM, 
SAS/STAT software, version 9.1.3, SAS institute Inc., Cary, NC, USA), where 
concentration was modeled as a linear function of the allele count (0,1,2). 
The selection of covariates in the final analyses was based on a preliminary 
analysis of the effect of potentially important confounders, i.e. back-length, 
weight, gender, age at lumbar puncture, and presence of a lifetime psychiatric 
diagnosis, on CSF monoamine metabolite concentrations, excluding the SNPs. 
CSF 5-HIAA and HVA concentrations were influenced by back-length and 
presence of a lifetime psychiatric diagnosis, whereas CSF MHPG 
concentrations were influenced by back-length and gender. 
Hardy–Weinberg equilibrium (HWE) was tested using Fisher’s exact test as 
implemented in PEDSTATS (Wigginton and Abecasis, 2005). The normal 
distribution of residuals was tested with the Anderson–Darling test, and 
residuals were approximately normally distributed after a square root 
transformation in the case of 5-HIAA and HVA and a logarithmic 
transformation in the case of MHPG. 
Correction for multiple testing was done through randomly permuting the 
marker genotypes among individuals and recalculating p-values for each 
permuted data set (1000 permuted data sets). The corrected p-value was then 
calculated as the fraction of permutated data sets where the minimum p-value 
was equal to, or smaller than, the observed p-value. 
Haploview 4.0 was used for calculation and virtualization of LD and for 
haplotype block estimation (Barrett et al., 2005). In Study I, the haplotype 
analysis was performed with UNPHASED (Dudbridge, 2008) , using all five 
SNPs and covariates as described above. 
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3.4.2 Studies IV-V 
In the second part of the study (Studies IV and V), the associations between 
SNPs and CSF MM concentrations were tested with multiple linear regression 
using STATA 12.1 (StataCorp. 2011. Stata Statistical Software: Release 12. 
College Station, TX: StataCorp LP), where concentration was modeled as a 
linear function of the allele count (0,1,2).  
In the case of healthy controls, three covariates were included in the analysis, 
i.e. back-length, gender and age at lumbar puncture, whereas in the case of 
psychotic patients two more binary covariates were used, i.e. the diagnosis 
(schizophrenia spectrum psychosis or other psychosis) and the use of 
antipsychotics. Antipsychotic treatment was considered as present if the patient 
had taken antipsychotics during a three-week period prior to the lumbar 
puncture. 
HWE was tested using exact significance as implemented in STATA 12.1. 
Normality of residuals was checked graphically with STATA 12.1. Adjustments 
for multiple testing were performed using Bonferroni correction taking into 
account the total number of tests conducted in each study. In Study IV, 
adjustment for multiple testing was also performed using a less conservative 
correction, taking into account the number of tests conducted, restricted to the 
candidate SNPs. 
 
3.5 ETHICAL APPROVAL 
The studies of the present thesis were conducted in accordance with the 
Declaration of Helsinki and the project was approved by the Regional Research 
Ethics Committee in Stockholm (dnr 2009/1403-31/1) and the Ethics 
Committee of the Karolinska University Hospital (dnr 94-036). Written 
informed consent was obtained from all the participating subjects. 
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4 RESULTS 
 
4.1 STUDY I 
One out of the five investigated TPH1 SNPs, i.e. rs4537731, was found to be 
nominally associated with both CSF 5-HIAA and HVA (uncorrected p-values 
0.0028 and 0.0016, respectively) in healthy subjects (Figure 3).  Both 
associations remained significant after correction for multiple testing (p-values 
0.026 and 0.029, respectively). 
 
Figure 3. Cerebrospinal fluid (CSF) 5-hydroxyindole acetic acid (5-HIAA), 
homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) 
concentrations in control individuals as a function of the number rs4537731 G-alleles 
(p=0.003, 0.002 and 0.82 for 5-HIAA, HVA and MHPG, respectively). Least square 
means and standard errors are given. 
After the single marker association analysis, a haplotype association analysis 
was also carried out.  Five haplotypes were segregating in the population and a 
significant overall association was found between the TPH1 haplotypes and 
both CSF 5-HIAA and HVA concentrations (p-values 0.012 and 0.013, 
respectively). The concentrations of both 5-HIAA and HVA were found to be 
positively associated with the GTCCG haplotype and negatively associated 
with the ATCCG haplotype. No significant association between the TPH1 
SNPs or haplotypes and CSF MHPG concentrations was found. 
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4.2 STUDY II 
Three of the eleven investigated DTNBP1 SNPs, i.e.  rs2619538, rs760666, and 
rs909706, were found to be nominally associated with CSF HVA concentrations 
in healthy subjects.  After correction for multiple testing, only the association 
between rs2619538 and HVA remained significant (corrected p-value 0.01). 
HVA mean concentration decreased with 26 nmol/L with each copy of the minor 
allele (A) (Figure 4). 
 
Figure 4. Cerebrospinal fluid (CSF) 5-hydroxyindole acetic acid (5-HIAA) and 
homovanillic acid (HVA) concentrations in control individuals as a function of the 
number rs2619538 A-alleles (p=0.04 and p=0.01 for 5-HIAA and HVA, respectively). 
Least square means and standard errors are given. 
Two of the eleven investigated DTNBP1 SNPs, i.e. rs2619538 and rs760666, 
were nominally associated with CSF 5-HIAA concentrations in healthy 
Caucasians. After correction for multiple testing, only the association of 
rs2619538 remained significant (corrected p-value 0.04). 5-HIAA mean 
concentration decreased with 13 nmol/L with each copy of the minor allele (A) 
(Figure 4). 
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4.3 STUDY III 
Two of the four investigated DAOA SNPs, i.e.  rs3918342 (Figure 5) and 
rs1421292, were significantly associated with CSF HVA concentrations in 
healthy Caucasians, with corrected p-values 0.013 and 0.043, respectively. The 
two SNPs were in almost complete LD in Scandinavian population and 
rs1421292 explained no additional variation in HVA concentration on top of 
that explained by rs3918342. Rs3918342 was also found to be nominally 
associated with CSF 5-HIAA concentrations. 
 
Figure 5. Cerebrospinal fluid (CSF) homovanillic acid (HVA) concentration in healthy 
subjects as a function of the number rs3918342 T-alleles (corrected p-value=0.013). 
Least square means and standard errors are given. 
 
Regarding rs3918342, C homozygotes (C/C) had 50 nmol/l higher HVA mean 
concentration relative to both C/T and T/T carriers, whereas no difference on 
HVA mean concentration was detected between subjects carrying the C/T and 
T/T genotypes, suggesting a dominant pattern with the T allele as the dominant 
allele. As expected, a decrease of the uncorrected p-value from 0.0016 to 
0.0001 was observed, when a dominant model of segregation was applied. 
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4.4 STUDY IV 
Twelve, 12 and 18 of the 119 investigated SNPs were found to be nominally 
associated with CSF HVA, 5-HIAA and MHPG concentrations, respectively, in 
psychotic patients. The nominally associated SNPs are illustrated in Tables 1-3. 
When correction for multiple testing was performed applying a conservative 
Bonferroni correction, taking into account the total number of tests conducted 
(α= 0.05/396= 1.26x10-4), no associations remained significant. However,  a 
correction for multiple testing taking into account the number of tests 
conducted restricted to the 28 candidate SNPs was also performed (α= 
0.05/90= 5.56x10
-4
). In this case, one association remained significant, i.e. the 
association between the candidate MAOB SNP rs5905512 and CSF MHPG 
concentrations in psychotic men. Moreover, there were 42 nominal 
associations, which exceeded the expected number (20) of nominal 
associations. 
Separate tests were performed in healthy controls, investigating whether the 42 
nominal associations were also present in this subject group. The analyses 
revealed that 41 out of 42 associations were restricted to patients with 
psychosis (Tables 1-3). 
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Table 1. SNPs nominally associated with CSF HVA concentrations in psychotic 
patients. 
 Patients with psychosis 
(n=74; 45 men, 29 women) 
Healthy controls 
(n=111; 63 men, 48 women) 
HVA mean (S.D.) 178.6  (79.3) nmol/l 167.5 (68.4) nmol/l 
Gene SNP MAF(%) HWE
 
P MAF(%) HWE
 
P 
DDC  rs11238133 36 0.211 0.004 41 1.000 0.757 
DDC rs6951648 19 0.273 0.005 17 0.735 0.297 
DDC rs10499696 11 0.186 0.009 9 0.594 0.681 
DDC  rs921451 42 0.018 0.011 43 0.564 0.661 
DDC  rs9942686 21 0.723 0.017 23 1.000 0.305 
TH  rs10770141 33 0.608 0.023 40 1.000 0.433 
TPH1 rs211105 31 0.785 0.029 25 0.449 0.292 
TH  rs10840491 16 0.680 0.035 12 0.640 0.433 
DDC  rs6593011 15 0.652 0.038 13 0.208 0.959 
COMT rs165774 32 0.003 0.043 30 0.258 0.650 
TPH2 rs1872824 34 0.606 0.047 33 0.830 0.685 
TH  rs10840489 18 1.000 0.048 14 1.000 0.357 
 
Minor allele frequencies (MAF), p-values of testing for Hardy–Weinberg equilibrium (HWE) and 
p-values (P) from multiple linear regressions of single nucleotide polymorphisms (SNPs) 
nominally associated with homovanillic acid (HVA) concentrations in the cerebrospinal fluid of 
psychotic patients and the corresponding association statistics among healthy controls.   
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Table 2. SNPs nominally associated with CSF 5-HIAA concentrations in 
psychotic patients. 
 Patients with psychosis 
(n=74; 45 men, 29 women) 
Healthy controls 
(n=111; 63 men, 48 women) 
5-HIAA mean (S.D.) 93.1 (34) nmol/l 90.8 (36.2) nmol/l 
Gene SNP MAF(%) HWE
 
P MAF(%) HWE
 
P 
MAOB(women) rs2311013 3 1.000 0.009 4 1.000 0.866 
MAOB(women) rs1181252 3 1.000 0.009 4 1.000 0.053 
DDC rs9942686 21 0.723 0.009 23 1.000 0.069 
DDC rs11238133 36 0.211 0.012 41 1.000 0.516 
DBH rs1611118 7 1.000 0.014 7 0.397 0.895 
DDC rs11238131 30 0.784 0.019 32 0.826 0.829 
MAOA (men)  rs5906957 31  0.027 17  0.089 
DDC rs11575535 4 1.000 0.035 4 1.000 0.302 
TPH1 rs1799913 42 0.096 0.039 41 0.334 0.330 
DBH rs6271 3 1.000 0.047 5 1.000 0.528 
MAOA (men) rs4301558 36  0.048 20  0.123 
MAOA (men) rs3027396 36  0.048 21  0.299 
 
Minor allele frequencies (MAF), p-values of testing for Hardy–Weinberg equilibrium (HWE) and 
p-values (P) from multiple linear regressions of single nucleotide polymorphisms (SNPs) 
nominally associated with 5-hydroxyindoleacetic acid (5-HIAA) concentrations in the 
cerebrospinal fluid of psychotic patients and the corresponding association statistics among 
healthy controls. MAOA and MAOB are located on chromosome X and the analyses were 
therefore conducted separately for men and women.  
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Table 3. SNPs nominally associated with CSF MHPG concentrations in 
psychotic patients. 
 Patients with psychosis 
(n=74; 45 men, 29 women) 
Healthy controls 
(n=111; 63 men, 48 women) 
MHPG  mean (S.D.) 43.3 (9.3) nmol/l 41.7 (8.1) nmol/l 
Gene SNP MAF(%) HWE
 
P MAF(%) HWE
 
P 
MAOB(men) rs5905512 47  0.0004 50  0.479 
MAOB (men) rs1799836 38  0.0008 44  0.483 
DDC rs11575535 4 1.000 0.005 4 1.000 0.126 
TPH1 rs4537731 44 0.475 0.007 40 0.047 0.646 
DDC rs6592961 28 0.400 0.008 29 0.104 0.855 
TPH1 rs7933505 41 0.148 0.010 41 0.334 0.342 
DDC rs7809758 40 0.811 0.013 38 0.159 0.956 
TPH1 rs7122118 43 0.239 0.014 40 0.029 0.821 
DBH rs6271 3 1.000 0.017 5 1.000 0.340 
TPH1 rs1799913 42 0.096 0.017 41 0.334 0.342 
TPH1 rs684302 42 0.232 0.017 41 0.171 0.397 
DDC rs9942686 21 0.723 0.018 23 1.000 0.189 
MAOB (men) rs6651806 24  0.021 32  0.328 
DDC rs17133853 11 1.000 0.033 9 0.569 0.436 
DBH rs1611115 21 1.000 0.035 14 1.000 0.791 
DBH rs3025388 18 0.445 0.047 18 0.517 0.064 
TPH1 rs12292915 44 0.161 0.047 43 0.052 0.066 
TPH1 rs211105 31 0.785 0.049 25 0.449 0.033 
 
Minor allele frequencies (MAF), p-values of testing for Hardy–Weinberg equilibrium (HWE) and 
p-values (P) from multiple linear regressions of single nucleotide polymorphisms (SNPs) 
nominally associated with 3-methoxy-4-hydroxyphenylglycol (MHPG) concentrations in the 
cerebrospinal fluid of psychotic patients and the corresponding association statistics among 
healthy controls. MAOA and MAOB are located on chromosome X and the analyses were 
therefore conducted separately for men and women.  
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4.5 STUDY V 
In psychotic patients, 13, 16 and nine of the 238 genotyped SNPs were 
nominally associated with CSF HVA, 5-HIAA and MHPG concentrations, 
respectively. The associated SNPs are illustrated in Tables 4-6. None of the 
nominal associations remained significant after correction for multiple testing. 
In order to investigate whether the 38 nominal associations were restricted in 
psychosis, separate tests were conducted in healthy controls. The analyses 
showed that five associations were also present in healthy subjects, whereas the 
other 33 associations were restricted to patients with psychosis (Tables 4-6). 
 
Table 4. Minor allele frequencies (MAF), p-values for Hardy–Weinberg 
equilibrium tests (HWE) and p-values (P) from nominal associations between 
single nucleotide polymorphisms (SNPs) and cerebrospinal fluid homovanillic 
acid (HVA) concentrations in psychotic patients. Corresponding association 
statistics among healthy controls.   
 Patients with psychosis 
(n=74; 45 men, 29 women) 
Healthy controls 
(n=111; 63 men, 48 women) 
HVA mean (S.D.) 178.6  (79.3) nmol/l 167.5 (68.4) nmol/l 
Gene SNP MAF(%) HWE
 
P MAF(%) HWE
 
P 
DISC1 rs12046794 11 0.590 0.001 9 0.173 0.435 
DISC1 rs1934909 14 1.000 0.007 14 0.123 0.964 
DISC1 rs10158776 2 1.000 0.013 1 1.000 0.970 
IDO1 rs6991530 14 1.000 0.015 14 1.000 0.290 
DAO rs17041020 7 1.000 0.021 5 1.000 0.040 
DISC1 rs823162 7 0.042 0.022 5 1.000 0.402 
DISC1 rs4325116 39 0.462 0.034 37 0.838 0.904 
DISC1 rs4385690 18 1.000 0.038 24 0.203 0.717 
DAOA rs1421292 43 0.344 0.040 42 0.561 0.006 
DISC1 rs1322783 12 0.277 0.043 15 0.280 0.878 
DAOA rs3916971 47 0.066 0.045 47 0.849 0.009 
DISC1 rs16854967 14 0.609 0.049 14 0.468 0.925 
DAO rs2070586 14 1.000 0.049 19 0.355 0.790 
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Table 5. Minor allele frequencies (MAF), p-values for Hardy–Weinberg 
equilibrium tests (HWE) and p-values (P) from nominal associations between 
single nucleotide polymorphisms (SNPs) and cerebrospinal fluid 5-
hydroxyindoleacetic acid (5-HIAA) concentrations in psychotic patients. 
Corresponding association statistics among healthy controls.    
 Patients with psychosis 
(n=74; 45 men, 29 women) 
Healthy controls 
(n=111; 63 men, 48 women) 
5-HIAA mean (S.D.) 93.1 (34) nmol/l 90.8 (36.2) nmol/l 
Gene SNP MAF(%) HWE
 
P MAF(%) HWE
 
P 
DAOA rs3918342 47 0.647 0.002 46 0.703 0.072 
DISC1 rs1934909 14 1.000 0.010 14 0.123 0.400 
DAOA rs1421292 43 0.344 0.010 42 0.561 0.085 
DISC1 rs1331056 45 0.154 0.012 40 0.844 0.131 
DAOA rs3916971 47 0.066 0.018 47 0.849 0.093 
GRIN1 rs28489906 47 0.100 0.025 48 1.000 0.500 
KMO rs1932441 29 0.395 0.026 36 0.680 0.093 
IDO1 rs6991530 14 1.000 0.028 14 1.000 0.194 
DISC1 rs2806465 50 0.062 0.033 45 0.443 0.033 
KMO rs12410855 36 0.079 0.034 36 0.681 0.946 
DAOA rs778293 43 0.237 0.034 42 1.000 0.049 
DISC1 rs12046794 11 0.590 0.035 8 0.484 0.365 
DISC1 rs17820909 10 1.000 0.036 6 1.000 0.597 
DTNBP1 rs12525702 9 0.438 0.040 8 0.115 0.250 
DTNBP1 rs3829893 11 0.031 0.042 10 0.321 0.656 
DISC1 rs9726024 34 0.606 0.048 34 0.403 0.158 
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Table 6. Minor allele frequencies (MAF), p-values for Hardy–Weinberg 
equilibrium tests (HWE) and p-values (P) from nominal associations between 
single nucleotide polymorphisms (SNPs) and cerebrospinal fluid 3-methoxy-4-
hydroxyphenylglycol (MHPG) concentrations in psychotic patients. 
Corresponding association statistics among healthy controls.     
 Patients with psychosis 
(n=74; 45 men, 29 women) 
Healthy controls 
(n=111; 63 men, 48 women) 
MHPG  mean (S.D.) 43.3 (9.3) nmol/l 41.7 (8.1) nmol/l 
Gene SNP MAF(%) HWE
 
P MAF(%) HWE
 
P 
KMO rs2275163 39 0.808 0.003 35 0.290 0.965 
KMO rs4660103 33 1.000 0.003 29 0.242 0.558 
KMO rs6677357 28 1.000 0.005 26 0.622 0.877 
DISC1 rs1934909 14 1.000 0.015 14 0.123 0.574 
KMO rs12138459 27 0.769 0.024 28 0.485 0.938 
DISC1 rs2812385 42 0.474 0.026 28 1.000 0.775 
DAOA rs1570709 22 0.165 0.026 22 0.096 0.447 
IDO1 rs7010461 35 0.619 0.028 29 0.167 0.952 
KMO rs2050516 47 0.647 0.044 40 0.691 0.714 
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5 DISCUSSION 
 
5.1 METHODOLOGICAL CONSIDERATIONS 
A candidate SNP approach was used in the first part of the thesis resulting in a 
limited number of statistical tests conducted and significant associations in all 
studies (Studies I-III), even after a correction for multiple testing. The limitation 
of this approach is the fact that other possibly relevant SNPs relative to MM are 
not included. This is not an issue in the second part of the thesis (Studies IV-V), 
as both candidate SNPs and tag-SNPs were genotyped. A limitation of this 
approach is the limited power to detect true associations, after a correction for 
multiple testing, due the relatively small number of both patients and controls, 
relative to the large number of tests conducted. In other words, there is an 
increased risk of false negative results (type II errors) and that could explain the 
fact that no significant associations were found in Studies IV or V, applying a 
conservative Bonferroni correction. 
When a less conservative approach was applied, taking into account the total 
number of tests conducted restricted to the candidate SNPs tested, the association 
between one candidate SNP, the intronic MAOB rs5905512, and MHPG 
concentrations in psychotic men remained significant (Study IV). Another 
approach is to consider that the genes selected in the second part of the thesis, 
mainly in Study IV, are highly likely to have an effect on CSF MM. Giving such 
a strong a priori hypothesis, it may be argued that a correction for multiple 
testing is not necessary (Rothman, 2014). Therefore, all the nominal associations 
are illustrated in Tables 1-6 and the most relevant nominal results are discussed.  
 
5.2 ANTIPSYCHOTICS 
A general issue in all studies regarding psychosis concerns the medication effects 
on the associations under investigation. In the second part of the thesis, where 
psychotic patients participated, we performed preliminary analyses in order to 
evaluate the effect of antipsychotics on CSF MM concentrations. Mean CSF 
MHPG concentration was significantly lower in patients who were under 
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treatment compared to antipsychotic-free patients, whereas mean CSF HVA and 
5-HIAA concentrations were not found to be associated with antipsychotic 
treatment. As our independent variables, the SNPs, are not expected to be 
associated with the antipsychotic treatment and moreover the use of 
antipsychotics was included as a covariate in the multiple linear regressions, the 
antipsychotic treatment should not confound our analyses. 
 
5.3 STUDY I 
One TPH1 SNP, rs4537731, located upstream the TPH1 gene, was found to be 
significantly associated with both CSF 5-HIAA and HVA in healthy subjects. 
As TPH is the rate-limiting enzyme of the serotonin synthesis, TPH1 gene 
variation is expected to affect the major serotonin metabolite 5-HIAA.  The 
association between TPH1 and the major dopamine metabolite HVA is also 
expected, due to the well-established relationship between 5-HIAA and HVA in 
CSF (Hsiao et al., 1993; Ågren et al., 1986). Finally, the lack of association 
between TPH1 gene variants and MHPG is also expected, as TPH is not 
implicated in norepinephrine synthesis (Figure 1). The present result is not in 
agreement with Galfalvy et al. (2009), who did not find any association 
between the rs4537731 polymorphism and MM concentrations in patients with 
major depression (Galfalvy et al., 2009). 
In the present study, the TPH1 rs4537731 A-allele was associated with 
decreased CSF 5-HIAA and HVA concentrations. The rs4537731 A-allele has 
been previously associated with suicide attempts among violent offenders and 
arsonists (Rotondo et al., 1999), and the AA-genotype with suicide attempts 
among patients with major depression (Galfalvy et al., 2009). We could 
therefore suggest that the associations between A-allele/AA-genotype and a 
higher risk for suicide attempts may be mediated by disturbed serotonin and 
dopamine turnover rates in CNS, reflected by decreased CSF 5-HIAA and HVA 
concentrations, respectively. However, we need to be cautious, as our results 
come from analyses of healthy subjects and moreover other studies, including a 
meta-analysis, have not found evidence for association between rs4537731 and 
suicidal behavior (Li and He, 2006). 
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The best studied TPH1 SNP, regarding CSF monoamine metabolite 
concentrations, is the intronic rs1799913. In the present study, no association 
was found between this SNP or another intronic TPH1 rs1800532, in almost 
complete LD with rs1799913 in Caucasians, and MM CSF concentrations. 
Thus, we have not been able to replicate previously reported associations 
between rs1799913 and CSF 5-HIAA in healthy controls (Jönsson et al., 1997) 
and violent offenders (Nielsen et al., 1994).  However, the lack of association, 
found in the present study, is in agreement with a study of Nielsen et al. (1998), 
who also failed to replicate the results of Jönsson et al. (1997) and Nielsen et 
al. (1994), reporting lack of association between rs1799913 and CSF 5-HIAA 
in violent and non-violent offenders as well as in healthy controls (Nielsen et 
al., 1998). Our results are also in agreement with a more recent association 
study, which failed to find any association between rs1800532 polymorphism 
and MM concentrations in patients with major depression or bipolar disorder 
(Galfalvy et al., 2009). 
The divergent results regarding TPH1 SNPs and CSF MM concentrations may 
be explained by the non-inclusion of back-length as a covariate in all studies, 
as well as by the fact that populations with different characteristics regarding 
ethnicity and psychiatric profile were analyzed. 
 
5.4 STUDY II 
One DTNBP1 SNP, rs2619538, was significantly associated with CSF HVA 
concentrations in healthy subjects. Rs2619538, located 1.5 kb upstream the 
only identified promoter region of the DTNBP1 gene (Pedrosa et al., 2009), has 
been associated with schizophrenia (Riley et al., 2009; Williams et al., 2004) as 
well as with negative and manic symptoms in psychotic patients (Corvin et al., 
2008). 
The present result supports the notion that DTNBP1 gene variation 
significantly affects the dopamine system, as reflected by the CSF HVA 
concentrations, in healthy individuals. This effect is possibly mediated by the 
BLOC-1 complex (Iizuka et al., 2007) and is in accordance with animal studies 
showing association between the DTNBP1 gene and its product dysbindin and 
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the dopamine system. The most robust evidence of association between 
DTNBP1 and the dopamine system is the significant reduction of dopamine 
content in different brain regions in Sandy mice (Murotani et al., 2007). Sandy 
mice have a large deletion in the DTNBP1 gene, resulting in essentially total 
loss of dysbindin (Li et al., 2003). 
Rs2619538 was also found to be significantly associated with CSF 5-HIAA in 
healthy individuals. Taking into account the lack of association between the 
almost total loss of dysbindin and a serotonin response in animal studies (Nagai 
et al., 2010), we conclude that this association may be due to the correlation 
between CSF 5-HIAA and HVA, which is among the most well-established in 
human CSF research (Geracioti et al., 1998). A direct association between 
DTNBP1 and the serotonin system, despite lack of associations in animal 
studies, may also be considered. 
 
5.5 STUDY III 
Two DAOA SNPs in almost complete LD, rs3918342 and rs1421292, were 
significantly associated with CSF HVA concentrations in healthy subjects. As 
rs1421292 explained no additional variation in HVA concentration on top of 
that explained by rs3918342, only rs3918342 is discussed.  
The TT genotype of the DAOA rs3918342 has been reported to be associated 
with attention and memory deficits in schizophrenia (Goldberg et al., 2006), 
decreased hippocampal activation and increased prefrontal activation in 
individuals at high genetic risk for schizophrenia (Hall et al., 2008) and with 
temporal lobe and amygdala gray matter reduction in bipolar disorder (Zuliani 
et al., 2009). In the present study, the TT genotype was associated with 
significantly lower HVA concentrations (Figure 5), suggesting that a disturbed 
dopamine turnover rate in CNS, reflected by decreased CSF HVA 
concentrations, may be a possible intermediate mechanism in the previously 
reported associations. A substantial limitation of this suggestion is the fact that 
the results of the present study concern healthy individuals and not patients 
with schizophrenia or bipolar disorder. 
 36 
5.6 STUDY IV 
MAOB rs5905512, located in intron 1, was one of the candidate SNPs selected 
due to its reported association with schizophrenia. The association between 
MAOB rs5905512 and CSF MHPG concentration in psychotic men showed the 
lowest p-value (uncorrected p-value 0.0004) in the present study. Moreover, 
this association remained statistically significant, taking into account the total 
number of tests conducted restricted to the candidate SNPs tested. Rs5905512 
was not found to be associated with CSF MM concentrations in women with 
psychosis, healthy men or healthy women. A literature search showed that two 
independent studies have searched for association between MAOB rs5905512 
and schizophrenia (www.szgene.org). The first study reported a significant 
association between this SNP and schizophrenia only in men (Carrera et al., 
2009), which is in accordance with our result, whereas the second study did not 
find any associations in either gender (Mas et al., 2009). The present result 
suggest that noradrenaline turnover rates, as reflected by the CSF MHPG 
concentrations, can be considered as an intermediate phenotype in the 
association between MAOB rs5905512 and psychosis in men. 
Some of the nominally associations illustrated in Tables 1-3 are further 
described, due to previously reported associations between the SNPs and 
schizophrenia. All these associations are restricted to psychosis, as they were 
not present in healthy controls. 
Two DBH SNPs, i.e. rs1611115 and rs6271, were associated with MHPG 
concentrations and rs6271 was also associated with 5-HIAA concentrations in 
psychotic patients. Rs1611115 is located upstream of DBH and accounts for 
31% to 52% of the variance of plasma DBH activity in different populations 
(Zabetian et al., 2001), whereas the nonsynonymous exonic rs6271 
independently accounts for additional variance (Tang et al., 2005).  Moreover, 
rs6271 has been associated with schizophrenia as well as with bipolar disorder 
(Ates et al., 2013; Kukshal et al., 2013). Taken together, the results suggest that 
noradrenergic and serotonergic mechanisms may mediate the previously 
reported association between this exonic DBH SNP and psychosis. 
TPH1 rs1799913, reported to be associated with schizophrenia in single studies 
and a meta-analysis (www.szgene.org), was in the present study associated 
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with both CSF 5-HIAA and MHPG, proposing that the previously reported 
associations with schizophrenia may be mediated by altered serotonin and 
noradrenalin turnover rates. 
The intronic MAOB rs1799836 was found to be nominally associated with 
MHPG concentrations in men with psychosis (uncorrected p-value 0.001). This 
MAOB SNP has been reported to be associated with schizophrenia in women 
(Gasso et al., 2008), as well as with altered enzyme activity in vitro and in vivo 
(Balciuniene et al., 2002; Costa-Mallen et al., 2005). 
The intronic COMT rs165774 was nominally associated with HVA 
concentrations in psychosis. Rs165774 showed departure from HWE in 
psychotic patients but not in healthy controls. As rs165774 has been reported to 
be significantly associated with schizophrenia (Voisey et al., 2012), the present 
result suggests that dopaminergic mechanisms may be an intermediate step 
between the gene variant and the disorder. 
 
5.7 STUDY V 
An extensive literature search has shown that a number of the psychosis 
associated SNPs, shown in Tables 4-6, have been ascribed some functionality 
or association with schizophrenia or other mental disorders. 
DAOA rs3918342 has been associated with schizophrenia as well as with 
bipolar disorder in independent studies (Bass et al., 2009; Korostishevsky et 
al., 2004; Ma et al., 2009; Schumacher et al., 2004). DAOA rs778293 has also 
been associated with schizophrenia (Korostishevsky et al., 2004; Ma et al., 
2006; Ma et al., 2009). In the present study, both rs3918342 and rs778293 were 
found to be associated with 5-HIAA concentrations in psychotic patients. 
Rs778293 was also found to be associated with 5-HIAA in controls. 
Rs3918342, located 28 Kb downstream of the DAOA gene, showed the lowest 
p-value (0.002) in association with 5-HIAA concentrations in psychosis and 
moreover this association was restricted in psychotic patients. We can therefore 
conclude that a disturbed serotonin turnover rate in CNS may be an 
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intermediate phenotype in the previously reported association between 
rs3918342 and schizophrenia. 
DAOA rs1421292 and rs3916971, located 40 kbp and four kbp downstream of 
the DAOA gene, respectively, have been associated with schizophrenia 
(Korostishevsky et al., 2004; Schumacher et al., 2004). Our results showed that 
both SNPs were associated with CSF HVA and 5-HIAA in patients with 
psychosis. Both SNPs were also associated with HVA in healthy controls, 
whereas the associations with 5-HIAA were absent in controls, suggesting that 
serotonergic mechanisms may be intermediate steps in the associations 
between DAOA rs1421292 and rs3916971 and psychosis. 
DAOA rs1570709, associated with MHPG concentrations in psychotic patients 
only, has been previously reported to be associated with schizophrenia (Opgen-
Rhein et al., 2008). Taken together, our results support the notion that 
noradrenergic mechanisms may modulate the association between rs1570709 
and psychosis. 
The intronic DAO SNP rs2070586, associated with HVA concentrations in 
psychotic patients only, has been reported to be associated with schizophrenia 
(Kim et al., 2010), proposing that the association between the SNP and 
psychosis may be due to dopaminergic mechanisms. 
The intronic KMO SNP rs2275163 showed the lowest p-value (0.003) in 
association with MHPG in psychosis and moreover this association was not 
present in healthy subjects. As the rs2275163 has been associated with 
schizophrenia (Aoyama et al., 2006), our result suggests that noradrenergic 
neurotransmission may play a role in this reported association between the 
KMO SNP and the disorder. 
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6 CONCLUSIONS 
 
In healthy individuals, TPH1 and DTNBP1 gene variants were significantly 
associated with both dopaminergic and serotonergic neurotransmission, as 
reflected by the CSF HVA and 5-HIAA concentrations, respectively. Moreover, 
DAOA SNPs were significantly associated with CSF HVA in healthy 
individuals, suggesting that the DAOA gene has an effect on dopamine turnover 
rate in CNS.  
In psychotic patients, nominal associations were found between SNPs in genes 
encoding enzymes implicated in the monoamine pathways and the CSF 
concentrations of HVA, 5-HIAA and MHPG. The number of the nominal 
associations exceeded the expected number and moreover all but one 
associations were absent in healthy controls. A candidate MAOB SNP, 
previously reported to be associated with schizophrenia in men, was found to be 
significantly associated with MHPG concentrations in men with psychosis, 
correcting for multiple testing taking into account the number of candidate SNPs 
included in the study. Some of the nominally associated SNPs in DBH, TPH1, 
MAOB and COMT have also been reported to be associated with schizophrenia. 
The present results suggest that altered monoamine turnover rates in CNS may 
represent intermediate steps in the associations between genes related to 
monoamine metabolism and psychosis.  
In psychotic patients, we have also found nominal associations between SNPs in 
glutamate–related genes and the CSF concentrations of HVA, 5-HIAA and 
MHPG. The majority of the nominal associations were absent in healthy 
individuals. Some of the nominally associated SNPs in DAOA, DAO and KMO 
have been previously reported to be associated with schizophrenia. The results 
suggest that CSF monoamine metabolite concentrations may represent 
intermediate phenotypes in the associations between glutamate-related genes and 
psychosis.  
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7 FUTURE RESEARCH 
 
In the present thesis, we were able to find significant and nominal associations 
between gene variants and CSF MM in healthy individuals and psychotic 
patients. Our findings need replication in independent studies using the candidate 
gene approach. GWAS are also a subject of future research, where without a 
priori hypothesis the whole human genome can be investigated for associations 
with CSF MM. To our knowledge, there are no GWAS studies conducted, 
searching for association between SNPs and MM in psychosis. Given a large 
sample, a GWAS study could shed further light revealing genes not being 
included in candidate gene studies, due to absence of known functionality 
relative to dopamine, serotonin and noradrenaline neurotransmission.     
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